Targeted Cancer Therapy with Monoclonal Antibodies and Tyrosine Kinase Inhibitors

Mechanism and Clinical Differences

The American Association for Cancer Research recommends understanding the distinct mechanisms of monoclonal antibodies and tyrosine kinase inhibitors, as they target the same pathways but through different mechanisms, with mAbs binding to extracellular receptor domains and TKIs inhibiting intracellular tyrosine kinase activity 1
The National Comprehensive Cancer Network suggests that TKIs, such as osimertinib, can inhibit both EGFR-sensitizing mutations and T790M resistance mutation by blocking intracellular tyrosine kinase activity, with a category 1 recommendation for first-line therapy in EGFR-mutant NSCLC 2, 5

The European Society for Medical Oncology notes that cetuximab, a monoclonal antibody, binds to the extracellular domain of EGFR, preventing ligand binding and receptor dimerization, with a recommended use in combination with chemotherapy in first-line metastatic colorectal cancer 1, 4
The American Society of Clinical Oncology recommends osimertinib as a preferred first-line therapy for EGFR exon 19 deletion or exon 21 L858R mutations in NSCLC, with a category 1 recommendation 5

The European Society for Medical Oncology reports that bevacizumab, a monoclonal antibody, has a prolonged half-life of 20 days and slow clearance, with class-specific toxicities including hypertension, proteinuria, and arterial thrombosis 6
The National Comprehensive Cancer Network notes that TKIs, such as erlotinib and gefitinib, have a higher risk of diarrhea and rash, with a recommended monitoring of liver enzymes and neutropenia 2, 3

The National Comprehensive Cancer Network recommends a clinical decision algorithm for EGFR-mutant NSCLC, with osimertinib monotherapy as the preferred first-line therapy, and combination therapy with pemetrexed and platinum as an alternative first-line option 5
The European Society for Medical Oncology suggests a clinical decision algorithm for metastatic colorectal cancer, with bevacizumab combined with FOLFOX, FOLFIRI, or 5-FU/LV/capecitabine as a first-line option, and continuation of bevacizumab through second-line therapy 6

The American Association for Cancer Research warns against assuming equivalence between mAbs and TKIs targeting the same pathway, as they have distinct mechanisms, toxicity profiles, and clinical contexts 1
The National Comprehensive Cancer Network notes that resistance mechanisms differ between TKIs and mAbs, with TKIs commonly developing point mutations and mAbs involving ligand-independent activation or alternative pathway upregulation 2, 5